Aralez To Announce Fourth Quarter And Full-Year 2017 Results On March 13, 2018

-Executive Management to Host Conference Call on March 13, 2018 at 8:30 a.m. ET-

MISSISSAUGA, Ontario, March 6, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its 2017 fourth quarter and full-year financial results on Tuesday, March 13, 2018, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET on such date to discuss the financial results, recent highlights and financial guidance for 2018.

Audio Webcast/ Conference Call Details
Date: Tuesday, March 13, 2018
Time: 8:30 a.m. ET
Dial-in (U.S.): 877-407-8037
Dial-in (International): 201-689-8037

A live webcast and audio archive for the event may be accessed from the Investors section of the Aralez website at www.aralez.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for two weeks.

About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.

Aralez Pharmaceuticals US Inc. Contact
Nichol L. Ochsner
Executive Director, Investor Relations & Corporate Communications
732-754-2545
nochsner@aralez.com

View original content with multimedia:http://www.prnewswire.com/news-releases/aralez-to-announce-fourth-quarter-and-full-year-2017-results-on-march-13-2018-300608599.html

SOURCE Aralez Pharmaceuticals Inc.